What Pevaryl Depot Treats: Main Uses and Benefits

Pevaryl Depot is applied across domains where additional symptomatic support is needed, such as in vulvovaginal mycoses, a condition generally known as a vaginal yeast infection, specifically addressing infections caused by Candida species. The active ingredient, econazole nitrate, is classified as an antifungal agent for this therapeutic use. Pevaryl Depot is used in situations involving certain distressing symptoms, where it may assist with managing the fungal overgrowth.

The medication is considered relevant in conditions associated with acute or disruptive episodes where symptoms create noticeable physiological strain. It is generally used when short-term symptomatic assistance is needed, such as fungal infections that commonly follow a course of broad-spectrum antibiotics, providing supportive relief with the benefit of a single-application, sustained local action.

The treatment helps address symptom clusters that may become intense or disruptive, including symptoms related to inflammatory or irritative states (pruritus), a pronounced burning sensation, and local signs of inflammation. The treatment supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Acute Discomfort

Property	Description
Primary Indication	Conditions presenting with acute episodes of Vulvovaginal mycoses
Symptom Focus	Symptoms that create noticeable physiological strain (itching, burning, inflammation)
Clinical Context	Applied in clinical settings that involve acute symptom patterns (e.g., post-antibiotics)
Patient Benefit	Supports easing the overall symptom load and contributes to improved day-to-day comfort

---

Regulatory References

1. NIH DailyMed drug documentation

Who Can and Cannot Use Pevaryl Depot?

Pevaryl Depot's eligibility is strictly defined by regulatory documentation, identifying groups for whom use is prohibited, restricted, or requires special caution.

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated for individuals with a known hypersensitivity to the active ingredient, econazole nitrate, to any related imidazole antifungal preparations, or to any excipients in the vaginal ovule.

Age-Related Eligibility

Pevaryl Depot is intended for use in adult females. Use is not indicated or not established in the pediatric population, specifically children under the age of 16 years. No specific precautions are required solely for older adults.

Populations Requiring Conditional Use

• Pregnancy and Lactation: Use during the first trimester of pregnancy is avoided; use in later trimesters and during lactation requires caution and a determination of clear need.
• Concomitant Medication: Patients using oral anticoagulants (such as Warfarin) must use this medicine with caution, as increased monitoring of anticoagulant effects is necessary.
• Product Compatibility: Use is restricted with latex barrier contraceptives (condoms or diaphragms) due to the risk of the ovule's excipients damaging the latex material.

Interactions with other medicines and products

The official regulatory profile for econazole nitrate (the active ingredient in Pevaryl Depot) focuses on two primary areas: potential systemic interactions with certain medicines and local restrictions involving other vaginal products and contraceptives.

---

Systemic Drug Interaction Potential

Econazole is officially noted as a known inhibitor of the metabolic isoenzymes CYP3A4 and CYP2C9. This pharmacokinetic profile indicates a risk of systemic interaction with other medicines metabolized by these enzymes. Specifically, co-administration with Oral Anticoagulants, such as Warfarin or Acenocoumarol, has resulted in the enhancement of the anticoagulant effect. This is measured as an increase in the International Normalized Ratio (INR) or prothrombin time. Regulatory documentation indicates that the risk of this systemic interaction is heightened when conditions favor higher absorption, such as application to large body surface areas, the genital area, or under occlusion.

---

Local Restrictions and Non-Medicinal Interactions

Strict limitations exist concerning local co-administration. The product must not be used in conjunction with other internal or external treatment of the genitalia. Furthermore, the product’s components are documented to potentially damage the latex material used in contraceptive diaphragms or condoms, requiring their avoidance. Similarly, the local treatment may inactivate the intended efficacy of spermicidal contraceptives. No interactions with food, alcohol, supplements, or herbal products are explicitly documented in the official prescribing information for this dosage form.

How Pevaryl Depot Works

The action of Econazole Nitrate involves the disruption of fungal structural and physiological processes.

---

Blocking the Fungal Structural Pathway

This mechanism describes the drug's role as an inhibitor of the fungal enzyme 14-alpha demethylase (CYP51). By inhibiting this enzyme, the drug prevents the fungus from synthesizing ergosterol, the primary sterol essential for cell membrane structure. This blockage results in the accumulation of toxic precursor molecules, weakening the cellular boundary, and initiating a cascade of events that compromise cell viability.

---

Destabilizing the Fungal Cell Membrane

Beyond enzymatic inhibition, the molecule exerts a direct physical action on the existing fungal cell membrane lipids. This interaction disorganizes the membrane, significantly increasing its permeability. The physical destabilization and subsequent leakage of essential intracellular components leads to cellular functional impairment, resulting in the cessation of fungal growth or cellular destruction.

Official Administration and Dosing for Pevaryl Depot

The usage of Pevaryl Depot is based on established routes, dosing schedules, and administration procedures for the 150 mg econazole nitrate vaginal pessary. The administration is via the intravaginal route only.

Standard Adult Regimens

The use of the vaginal pessary typically involves two primary approaches. Dosing parameters generally include the following regimens:

Regimen Type	Dosage and Frequency	Duration
Prolonged-Release (Depot)	One 150 mg pessary	Single application
Multi-Dose Course	One 150 mg pessary once daily	Three consecutive days

Procedural Instructions and Timing

For proper local application, the pessary is inserted high into the vagina. The application typically occurs at night (before retiring/bedtime) to facilitate maximum action while the patient is recumbent.

Population and Co-Administration Rules

Use is not indicated for pediatric patients under 16 years of age. No specific dosage adjustments are typically stipulated for older adults. Furthermore, the product is characterized by the requirement that it should not be used in conjunction with other internal or external treatments applied to the genitalia.

Evidence for use in Vulvovaginal Mycoses (VVC)

The core research for Pevaryl Depot, which contains the active ingredient econazole nitrate, examined conditions such as acute or disruptive episodes, specifically vulvovaginal mycoses. The ovule formulation was evaluated in numerous Randomized Controlled Trials (RCTs) and comparative studies. These studies often explored the compound against an inactive substance (vehicle) or against other antifungal treatments used in comparison. This research was studied for its application in short-term or episodic symptom patterns and was observed in clinical settings evaluating daily-life functioning related to the infection.

---

Study Outcomes: Cure and Symptom Endpoints

Researchers in these trials established key measurement points, or outcomes, to assess the measures defined for the study. One primary measure used was Composite Cure, defined as the simultaneous observation of both fungal clearance and the measured change in physical signs of infection. Studies also closely monitored Mycological Cure, which is based on laboratory results indicating the absence of the specific fungal species. Furthermore, studies examined changes in measures of patient-reported discomfort, tracking outcomes such as the intensity of pruritus (itching) and the presence of a burning sensation.

---

Long-Term Follow-up and Evidence in Specific Populations

Research studies primarily used short-term or intermediate-term follow-up durations, assessing outcomes up to approximately four to six weeks post-treatment. Studies explored the relapse or recurrence rate during this defined time interval. Separately, research was evaluated in specific sub-groups, such as women with recurrent candidal infections. Population-based case-control studies and some clinical trials also examined the use of the ovules in pregnant women, primarily in the second and third trimesters.

---

What is Still Uncertain About the Research Record

The research record identifies evidence gaps and limitations. Follow-up durations were limited in many studies of this specific formulation, and there is limited information for long-term outcomes regarding the ovule’s effect on preventing infection recurrence beyond the intermediate-term window. Comparative evidence with certain newer topical treatments is also limited, and results apply only to the populations studied in the trials. These limitations indicate that the long-term effects are not fully established on the cycle of conditions characterized by fluctuating or episodic manifestations.

Common questions about Pevaryl Depot (FAQ)

---

Q: What specific type of fungal infections is Pevaryl Depot intended to treat?

According to official product information, this medicine is indicated for the local treatment of infections caused by fungi and yeasts. This primarily includes vulvovaginal candidiasis, which is caused by Candida species such as Candida albicans.

---

Q: How long does the single-dose 150 mg pessary continue to release the medicine for?

Pevaryl Depot is specially designed as a prolonged-release ovule, which means it provides a sustained and continuous delivery of the active ingredient at the site of infection. While the specific quantifiable duration of the release is not published in the patient-facing regulatory summaries, the formulation is designed to maintain therapeutic concentration for an extended period from a single application.

---

Q: When should I start to feel relief from my symptoms after using Pevaryl Depot?

Studies and official information for topical products containing the active ingredient, econazole nitrate, indicate that some patients may experience relief of their symptoms soon after treatment is started. Individual responses and relief timelines can vary.

---

Q: Can I have sex while I am using Pevaryl Depot?

Regulatory guidance and patient leaflets often note that, to avoid potential re-infection or risk of damage to latex contraceptives, a pause in intercourse during the treatment course may be advised. The ovule’s components are known to potentially damage or reduce the effectiveness of latex-based barrier contraceptives (condoms/diaphragms), which is a key reason for the restriction.

---

Q: Do I need a prescription from a doctor to buy Pevaryl Depot?

Official regulatory documents indicate that this medication is typically dispensed as a prescription-only product. This requires that a healthcare practitioner determine the appropriate course of treatment and authorize its use.

---

Q: What is the difference between Pevaryl Depot and the cream formulation?

Pevaryl Depot is a specialized prolonged-release vaginal ovule (pessary) designed for single or short-course intravaginal use. The cream formulation, where available, is a different dosage form applied using an applicator, and is often used for a longer course of treatment that may cover both internal and external fungal infections.

---

Q: Can Pevaryl Depot be used while menstruating?

Some official Patient Information Leaflets advise that patients do not interrupt or stop the treatment course if their menstrual period begins. The recommended course of treatment should be completed.

Storage Conditions

Official regulatory labeling for Pevaryl Depot (Econazole Nitrate Ovule) defines precise storage constraints to maintain product stability.

Storage Requirement	Specification
Temperature Limit	Do not store above 30 C (86 F).
Protection	Keep away from heat and sunlight.
Container Rule	Store in the original container.
Stability Check	Do not use if the plastic packet is broken or if the ovule is not white to off-white.

Disposal Instructions

Disposal must align with official protocols for pharmaceutical waste:

• Prohibited Disposal: Do not discard the medicine via wastewater or standard household waste.
• Required Procedure: Ask a pharmacist how to properly throw away unused or expired product. This measure is required to help protect the environment.
• Child Safety: Keep the medicine out of the sight and reach of children.